Temozolomide (TMZ) is a currently the first-line drug used for GBM treatment independent of the methylation state of O6-methylguanine methyltransferase(MGMT), which can induce DNA strand breaks during cell replication and thus promotes cell apoptosis(Hegi et al., 2019). Here, MGMT is linked to glioblastoma.